Luca Franceschini
Overview
Explore the profile of Luca Franceschini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fazio F, Gherardini M, Rossi E, Za T, Di Landro F, More S, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941726
Background/objectives: Treatments for multiple myeloma (MM) have expanded in the last decade, and the overall survival (OS) of MM patients (pts) is in continuous improvement. With the availability of new...
2.
Martino E, Palmieri S, Galli M, Derudas D, Mina R, Pepa R, et al.
Hematol Oncol
. 2024 May;
42(4):e3290.
PMID: 38818978
The ELOQUENT-3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who...
3.
Mannarino M, Bianconi V, Scalisi G, Franceschini L, Manni G, Cucci A, et al.
Front Immunol
. 2023 Apr;
14:964660.
PMID: 37081894
Background: Chronic systemic inflammation reduces the bioavailability of circulating endothelial progenitor cells (EPCs). Indoleamine 2,3-dioxygenase 1 (IDO1), a key enzyme of immune tolerance catalyzing the initial step of tryptophan degradation...
4.
Cordone I, Amodeo R, Bellesi S, Bottan F, Buccisano F, De Propris M, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046720
Flow cytometry is a highly sensitive and specific approach for discriminating between normal and clonal plasma cells in multiple myeloma. Uniform response criteria after treatment have been established by the...
5.
Fazio F, Franceschini L, Tomarchio V, Rago A, Garzia M, Cupelli L, et al.
EJHaem
. 2022 Jul;
3(1):121-128.
PMID: 35846211
The multiple myeloma (MM) treatment has changed over the last years due to the introduction of novel drugs. Despite improvements in the MM outcome, MM remains an incurable disease. Daratumumab...
6.
Ianniello Z, Sorci M, Ceci Ginistrelli L, Iaiza A, Marchioni M, Tito C, et al.
Cell Death Dis
. 2021 Sep;
12(10):870.
PMID: 34561421
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the presence of tyrosine kinase BCR-ABL1 fusion protein, which deregulate transcription and mRNA translation. Tyrosine kinase inhibitors (TKIs) are the...
7.
Santoleri F, Ranucci E, La Barba G, Colasanto I, Scaldaferri M, Cattel F, et al.
Curr Med Res Opin
. 2021 Jan;
37(3):477-481.
PMID: 33459083
Background: The use of dasatinib and nilotinib in the treatment of patients with chronic myeloid leukemia represents a valid therapeutic option for patients resistant or intolerant to imatinib. In this...
8.
Gurnari C, Lombardi A, Cosi E, Biagetti G, Buccisano F, Franceschini L, et al.
Br J Haematol
. 2019 Apr;
186(4):e100-e103.
PMID: 31016714
No abstract available.
9.
Bernardi S, Malagola M, Zanaglio C, Polverelli N, Dereli Eke E, DAdda M, et al.
Cancer Med
. 2019 Apr;
8(5):2041-2055.
PMID: 30950237
Treatment-free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation in patients with deep molecular response (DMR) is a paramount goal in the current chronic myeloid leukemia (CML) therapeutic strategy. The...
10.
Gurnari C, Franceschini L, Anemona L, Passarelli F, Vaccarini S, Pupo L, et al.
Clin Case Rep
. 2018 Oct;
6(10):1958-1960.
PMID: 30349706
We report on a case of Sweet's syndrome associated with multiple myeloma, as harbinger for disease relapse.